The Role of Serum CK18, TIMP1, and MMP-9 Levels in Predicting R0 Resection in Patients with Gastric Cancer

Table 1

Patient characteristics.

Age, ave. ± SD (min-max)		64.0 ± 12.2 (42–88)
Age, n (%)	<50-year-old	7 (14.0)
	50-70-year-old	26 (52.0)
	>70-year-old	17 (34.0)
Gender, n (%)	Male	34 (68.0)
	Female	16 (32.0)
Operation, n (%)	R0 resection	44 (88.0)
	Subtotal gastrectomy	24 (48.0)
	Total gastrectomy	20 (40.0)
	Palliative	6 (12.0)
Pathology, n (%)	Adenocancer	50 (100)
Tumor A, ave. ± SD (min-max)		34.1 ± 6.7 (21–47)
Clinical T, n (%)	3	40 (80.0)
	4	10 (20.0)
Clinical N, n (%)	Positive	19 (38.0)
Clinical stage, n (%)	2	30 (60.0)
	3	20 (40.0)
Pathological N, ave. ± SD (min-max)		7.5 ± 5.4 (1–18)
Total lymph node, ave. ± SD (min-max)		15.4 ± 6.2 (0–24)
Pathological stage, n (%)	2B	7 (14.0)
	3A	12 (24.0)
	3B	14 (28.0)
	3C	11 (22.0)
	4	6 (12.0)
Wound infection, n (%)		9 (18.0)
Anastomose leak, n (%)		9 (18.0)
Ileus, n (%)		4 (8.0)
Atelectasis, n (%)		4 (8.0)
Mortality, n (%)		14 (28.0)